

**The numbered pages
omitted from this article
are advertisements.**

Nature biotechnology.
v. 28, no. 2 (Feb. 2010)
General Collection
W1 B1918LW
2010-03-04 09:40:59

VOLUME 28 NUMBER 2 FEBRUARY 2010
www.nature.com/naturebiotechnology

biotechnology

THE SCIENCE AND BUSINESS OF BIOTECHNOLOGY




PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

Imaging hepatitis C virus infection in real time

Rational enhancement of siRNA delivery

Endothelial cells from pluripotent stem cells

nature biotechnology



Transmission electron micrograph of hepatitis C viruses. Rice and colleagues present a method to detect individual hepatitis C virus-infected cells using a fluorescent reporter molecule (p 167). Credit: James Cavallini/Photo Researchers, Inc.



US increased herbicide use linked with GM crops, p 112

EDITORIAL

- 103 PhRMA wants you!
- 103 Impossible fixes

NEWS

- 105 PML problems loom for Rituxan
- 107 Pfizer stakes a claim in plant cell-made biopharmaceuticals
- 109 Amylin's \$1 billion heavyweight deal
- 110 Peruvian GM advocate faces criminal charges
- 110 EC convenes crisis talks on European biotech sector
- 112 Irish bioethics council axed
- 112 Amgen trumps Roche
- 112 Report blames GM crops for herbicide spike, downplays pesticide reductions
- 114 Industry gains on money-back schemes
- 114 \$2 million rice verdict against Bayer
- 114 Biorefineries' stimulus win
- 115 Purpose-built chromosome
- 115 FDA balks on MedImmune's cell-grown flu vaccine
- 116 **DATA PAGE:** 2009: Turning the corner
- 117 **NEWS FEATURE:** The HER2 testing conundrum

BIOENTREPRENEUR

BUILDING A BUSINESS

- 120 Coming to terms
David H Oden, Jeffrey A Wolfson & Christina W Marshall

OPINION AND COMMENT


CORRESPONDENCE

- 123 Fab-arm exchange
- 126 An economic and technical evaluation of microalgal biofuels
- 128 Ontology engineering



nature publishing group

Nature Biotechnology (ISSN 1087-0156) is published monthly by Nature Publishing Group, a trading name of Nature America Inc., located at 75 Varick Street, F19, New York, NY 10013-1917. Periodicals postage paid at New York, NY and additional mailing post offices. **Editorial Office:** 75 Varick Street, F19, New York, NY 10013-1917. Tel: (212) 726-9335; Fax: (212) 696-9753. **Annual subscription rates:** USA/Canada: US\$250 (personal), US\$3,520 (institution), US\$4,050 (corporate institution); Canada add 5% GST #104911595RT001; Euro-zone: €202 (personal), €2,795 (institution), €3,488 (corporate institution); Rest of world (excluding China, Japan, Korea): £130 (personal), £1,806 (institution), £2,250 (corporate institution); Japan: Contact NPG Nature Asia-Pacific, Chiyoda Building, 2-37 Ichigayatamachi, Shinjuku-ku, Tokyo 162-0843. Tel: 81 (03) 3267 8751; Fax: 81 (03) 3267 8746. **POSTMASTER:** Send address changes to *Nature Biotechnology*, Subscriptions Department, 342 Broadway, PMB 301, New York, NY 10013-3910. **Authorization to photocopy** material for internal or personal use, or internal or personal use of specific clients, is granted by Nature Publishing Group to libraries and others registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided the relevant copyright fee is paid direct to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. Identification code for *Nature Biotechnology*: 1087-0156/04. **Back issues:** US\$45, Canada add 7% for GST. CPC PUB AGREEMENT #40032744. Printed by Publishers Press, Inc., Lebanon Junction, KY, USA. Copyright © 2010 Nature Publishing Group. Printed in USA.



Regulations to prevent outcrossing of GM pollen in the EU, p 133



Mining the maize genome, p 144



Computational discovery of plant gene function, p 149

COMMENTARY

- 131 **CASE STUDY: Never again**
Christopher Scott
- 133 **Going to ridiculous lengths—European coexistence regulations for GM crops**
Koreen Ramessar, Teresa Capell, Richard M Twyman & Paul Christou

FEATURE

PATENTS

- 137 **Changing the rules of the game: addressing the conflict between free access to scientific discovery and intellectual property rights**
Miriam Bentwich
- 141 **Recent patent applications in antibody fragments**

NEWS AND VIEWS

- 142 **ChIPs and regulatory bits**
Xin He & Saurabh Sinha
- 144 **From genomics to crop breeding**
Richard Flavell
- 145 **Spilling the beans on legume biology**
Peter Hare
- 146 **Systematic tracking of cell fate changes**
Jonghwan Kim & Stuart H Orkin
- 148 **RESEARCH HIGHLIGHTS**

COMPUTATIONAL BIOLOGY


RESOURCE

- 149 **Rational association of genes with traits using a genome-scale gene network for *Arabidopsis thaliana***
Insuk Lee, Bindu Ambaru, Pranjali Thakkar, Edward M Marcotte & Seung Y Rhee


RESEARCH

BRIEF COMMUNICATIONS

- 157 **Enhanced antibody half-life improves *in vivo* activity**
J Zalevsky, A K Chamberlain, H M Horton, S Karki, I W L Leung, T J Sproule, G A Lazar, D C Roopenian & J R Desjarlais



Endothelial cells from hESCs, p 161



Systematically improving siRNA delivery, p 172

LETTERS

- 161 Expansion and maintenance of human embryonic stem cell–derived endothelial cells by TGF β inhibition is Id1 dependent**
D James, H-s Nam, M Seandel, D Nolan, T Janovitz, M Tomishima, L Studer, G Lee, D Lyden, R Benezra, N Zaninovic, Z Rosenwaks, S Y Rabbany & S Rafii
- 167 Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system**
C T Jones, M T Catanese, L M J Law, S R Khetani, A J Syder, A Ploss, T S Oh, J W Schoggins, M R MacDonald, S N Bhatia & C M Rice
- 172 Rational design of cationic lipids for siRNA delivery**
S C Semple, A Akinc, J Chen, A P Sandhu, B L Mui, C K Cho, D W Y Sah, D Stebbing, E J Crosley, E Yaworski, I M Hafez, J R Dorkin, J Qin, K Lam, K G Rajeev, K F Wong, L B Jeffs, L Nechev, M L Eisenhardt, M Jayaraman, M Kazem, M A Maier, M Srinivasulu, M J Weinstein, Q Chen, R Alvarez, S A Barros, S De, S K Klimuk, T Borland, V Kosovrasti, W L Cantley, Y K Tam, M Manoharan, M A Ciufolini, M A Tracy, A de Fougères, I MacLachlan, P R Cullis, T D Madden & M J Hope

178 CORRIGENDA AND ERRATA

CAREERS AND RECRUITMENT

- 179 Fourth quarter lag in biotech hiring**
Michael Francisco
- 180 PEOPLE**

ADVERTISEMENT

Biotech in China

A special report analyzing China's emerging biotech and pharmaceutical industries. The main feature investigates the local strategies of western and Chinese organisations, assessing massive investment programs and a returning western trained skilled work force. Will China achieve its ambition to develop and innovative drug discovery industry to compliment its generics industry? How long do the experts believe it will be before China has its own home grown innovative new drug approved for the global markets? What are activities of western drug companies in China? The "Biotech in China" special report follows Letters on page 176 and is produced with the commercial support from the organizations featured in the Advertorial Partnering Profiles.




Endothelial cell recipe

Endothelial cells derived from pluripotent stem cells might one day provide the raw material for engineering or repairing blood vessels. To develop an improved method for vascular differentiation, Rafii and colleagues generate a human embryonic stem cell line that expresses green fluorescent protein under the control of the endothelial cell-specific VE-cadherin promoter. Using this reporter cell line to screen molecules involved in early developmental signaling, they find that inhibition of transforming growth factor (TGF) β beginning at day 7 of differentiation increases the yield of endothelial cells and maintains the cells' vascular phenotype for up to ten cell divisions. Mechanistic investigation identifies the transcription factor Id1 as a key mediator of the effects of TGF β inhibition.

[Letters, p. 161]

KA




Potent siRNA delivery

Empirical screening has revealed novel lipid nanoparticle formulations that have substantially enhanced *in vivo* delivery of therapeutic small interfering (si)RNAs. Now Semple *et al.* have set a new potency standard for siRNA delivery to the liver by adopting a more rational approach to the design of cationic lipids. They refined an empirically identified cationic lipid (1,2-dilinoleyloxy-3-dimethylaminopropane), widely regarded as the benchmark for use in lipid nanoparticles, by dividing the structure into three functional elements and then systematically testing modifications of each element in isolation. This strategy to reveal structure-activity relationships was guided by the putative role of cone-shaped lipids to induce nonbilayer phases, such as the hexagonal H_{II} phase illustrated here. When formulated to silence hepatic gene expression, the best-performing lipid variant conferred *in vivo* activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates.

[Letters, p. 172]


PH



Predicting plant gene function

Despite extensive mutant screening, the functions of many plant genes are still unknown. Lee *et al.* predict gene function in the model plant *Arabidopsis thaliana* by gauging the likelihood that pairs of genes are involved in the same biological processes. Each pair of genes is assigned a score that combines many types of experimental and computational data gathered in *Arabidopsis*. The score also incorporates data from other organisms, such as yeast, worm, fly and humans, on genes that show substantial sequence similarity to *Arabidopsis* genes. Then, the function of an *Arabidopsis* gene is predicted based on the scores linking it to other genes with known function. To demonstrate the utility of the approach, Lee *et al.* predicted and validated the roles of genes in seed pigmentation, lateral root development and drought sensitivity. By integrating multiple sources of data using methods customized for plants, Lee *et al.* predict gene function with greater confidence than by using only a single source of data. This study provides a resource for identifying genes that influence agriculturally and economically important plant traits. [Resource, p. 149]

CM



Lighting up HCV infection

Protocols for detecting hepatitis C virus infection without the need for complex manipulation of clinical samples or the use of genetically engineered viruses is of prime importance for many applications in basic research and drug development. Rice and colleagues have now developed a fluorescent reporter system that allows the detection of individual cells infected by wild-type viruses. The reporter molecule is based on a known target of a viral protease, interferon- β promoter stimulator protein 1 (IPS-1). The C-terminal part of IPS-1, including the mitochondrial targeting sequence and the protease cleavage site, is fused to a fluorescent protein and a nuclear localization sequence. Upon expression of the viral protease the construct is cleaved and the fluorescent protein relocates from the mitochondria to the nucleus. The authors use their reporter molecule to study viral propagation in living cells and the development of stress responses in cells after infection. They also demonstrate that primary hepatocytes can be infected with hepatitis C viruses *in vitro*. [Letters, p. 167]

ME



Written by Kathy Aschheim, Markus Elsner, Michael Francisco, Peter Hare, Craig Mak & Lisa Melton

Linking antibody half-life to efficacy

Mutations that improve the affinity of antibodies for the neonatal Fc receptor (FcRn) are known to enhance antibody longevity *in vivo*. Nonetheless, it has never been demonstrated that prolonged

exposure to Fc-engineered therapeutic antibodies necessarily enhances *in vivo* activity. Desjarlais and colleagues use cynomolgus monkeys and a humanized transgenic mouse model to show that the reduction in antibody clearance caused by increased antibody affinity for FcRn enhances the antitumor activities of antibodies targeted against either an internalizing surface receptor (epidermal growth factor receptor) or a cytokine (vascular endothelial growth factor). The enhanced pharmacokinetics associated with Fc-engineered variants may translate to greater convenience for patients, reduced costs and higher efficacy. [Brief Communications, p. 157] *PH*

Patent roundup

Bringing a five-year patent dispute to an end, a federal court in Boston has ruled that Roche's Mircera (methoxy polyethylene glycolepoetin beta) does, indeed, infringe on Amgen's patents and slapped the Swiss drugmaker with a permanent injunction banning sales in the US market. Roche has agreed to a limited license agreement with Amgen that will allow it to sell Mircera in the US until 2014. [News, p. 112] *LM*

To solve the conflict between free access to scientific discovery and intellectual property rights, Bentwich proposes a provisional patented paper application procedure that could promote earlier disclosure of novel scientific knowledge and justify the requirement to grant inexpensive licenses for using inventions for the advancement of other research. [Patent Article, p. 137] *MF*

Recent patent applications in antibody fragments. [New patents, p. 141] *MF*

Next month in

nature biotechnology

- Screening for drugs that reconfigure metabolism
- Leukemia stem cell quiescence and resistance to chemotherapy
- Directed evolution of an MRI contrast agent for dopamine
- Autophagy harnessed to clear mutant huntingtin protein

Enhanced antibody half-life improves *in vivo* activity

Jonathan Zalevsky^{1,3}, Aaron K Chamberlain¹, Holly M Horton¹, Sher Karki¹, Irene W L Leung¹, Thomas J Sproule², Greg A Lazar¹, Derry C Roopenian² & John R Desjarlais¹

Improved affinity for the neonatal Fc receptor (FcRn) is known to extend antibody half-life *in vivo*. However, this has never been linked with enhanced therapeutic efficacy. We tested whether antibodies with half-lives extended up to fivefold in human (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing intervals. We observed that prolonged exposure due to FcRn-mediated enhancement of half-life improved antitumor activity of Fc-engineered antibodies in an hFcRn/Rag1^{-/-} mouse model. This bridges the demand for dosing convenience with the clinical necessity of maintaining efficacy.

The well-established role of FcRn in IgG turnover has been the foundation for Fc engineering efforts aimed at improving the pharmacokinetic properties of therapeutic antibodies^{1,2}. Despite contrary results about the relationship between FcRn affinity and half-life^{3,4}, several such efforts at pharmacokinetic engineering in nonhuman primates, whose FcRn is similar to that of humans, have demonstrated that engineered antibody variants have a prolonged half-life^{5–8}. Yet, although the successful extension of half-life in pharmacokinetic experiments bodes well for the prospect of improving clinical dosing, a critical gap remains. For half-life extension technologies to be of practical use, efficacy of a biotherapeutic with longer half-life must be preserved at longer dosing intervals. Although the relationship between drug exposure and efficacy is well-established, this correlation has not thus far been established for antibodies engineered for longer half-life.

We coupled rational design methods with high-throughput protein screening to engineer a series of Fc variants with greater affinity for human FcRn. Variants were constructed in the context of the humanized anti-vascular endothelial growth factor (VEGF) IgG1 antibody bevacizumab⁹ (Avastin), which is currently approved for the treatment of colorectal, lung, breast and renal cancers. A description of the construction, production and binding studies of the antibodies is provided in **Supplementary Methods**. As FcRn binds IgG at the lower pH of the early endosome (pH 6.0–6.5) but not at the higher pH of blood (pH 7.4), we used Biacore to screen antibodies for binding to human FcRn at pH 6.0. Our engineered variants demonstrated between 3- and 20-fold greater binding to FcRn at pH 6.0, with improvements

due almost exclusively to slower off-rate (k_{off}) (**Supplementary Fig. 1** and **Supplementary Table 1**). A lead variant, M428L/N434S, subsequently selected principally based on its pharmacokinetic performance (see below), provided an 11-fold improvement in FcRn affinity at pH 6.0. We refer to this double substitution in the context of bevacizumab as Xtend-VEGF.

Details of a pharmacokinetic study in cynomolgus monkeys (*Macaca fascicularis*) to evaluate the capacity of the variants to improve serum half-life are provided in the **Supplementary Methods**. Binding improvements of the variants to monkey FcRn at pH 6.0 were comparable to improvements for human FcRn, and the rank order of the variants in FcRn affinity was the same (data not shown). When three monkeys per group were injected intravenously with 4 mg/kg variant or native IgG1 anti-VEGF antibody, we observed a large improvement in half-life for the variants relative to native IgG1 (**Supplementary Fig. 2a**). Fitted parameters for the full set of variants (**Supplementary Table 2**) indicated increases in β -phase half-life, area under the curve (AUC) measurements and the rate of antibody clearance from serum. The observed 9.7-d half-life for native IgG1 bevacizumab agrees with the published value (9.3 d) for a slightly lower (2 mg/kg) dose¹⁰. Among the engineered antibodies that were tested, the Xtend double variant performed best (**Fig. 1a**). It prolonged half-life from 9.7 to 31.1 d, a 3.2-fold improvement in serum half-life relative to native IgG1 (**Supplementary Table 2**). Simple allometric scaling extrapolations suggest that such improvement can potentially translate into human half-lives >50 d.

We then sought to further challenge the applicability of pharmacokinetic engineering by targeting an internalizing cell-surface antigen that potentially provides a competing sink for antibody clearance.




Figure 1 Increasing antibody affinity to FcRn promotes half-life extension in cynomolgus monkeys. **(a)** Log-linear changes in serum concentrations for anti-VEGF (bevacizumab) antibodies in cynomolgus monkeys. All antibodies were administered by single 60-min intravenous infusion at 4 mg/kg and serum antibody concentrations were determined using a VEGF antigen-down immunoassay. Results are means $\pm$ s.e.m. ($n = 2$ for bevacizumab and $n = 3$ for variants). **(b)** Log-linear changes in serum concentrations for anti-EGFR antibodies in cynomolgus monkeys. Monoclonal antibodies were administered by single 30-min intravenous infusion at 7.5 mg/kg and serum antibody concentrations were determined using an EGFR antigen-down immunoassay. Results are means ($n = 2$ animals per test article).

¹Xencor, Inc., Monrovia, California, USA. ²The Jackson Laboratory, Bar Harbor, Maine, USA. ³Present address: Takeda San Diego, Inc., San Diego, California, USA. Correspondence should be addressed to J.R.D. (jrd@xencor.com).




Figure 2 Improved antibody half-life translates to greater *in vivo* efficacy. (a) Log-linear changes in serum concentrations of anti-VEGF antibodies in hFcRn mice. All antibodies were administered via single intravenous bolus at 2 mg/kg, and serum antibody concentrations were determined using a human immunoglobulin recognition immunoassay. Results are means $\pm$ standard errors ($n = 6$). For some data points, errors are smaller than can be indicated. (b) Log-linear changes in serum concentrations of anti-EGFR antibodies in hFcRn mice. The study design was identical to that described in a, except that serum concentrations were measured with an EGFR antigen-down immunoassay. (c) Xenograft study in hFcRn/Rag1^{-/-} mice comparing activity of native IgG1 and Xtend variant versions of bevacizumab against established SKOV-3 tumors. Tumor volume is plotted against day after tumor cell injection. Antibodies were dosed at 5 mg/kg every 10 d starting on day 35 (indicated by the arrows). $n = 8$ mice/group. *, $P = 0.028$ at 84 d. (d) Xenograft study in hFcRn/Rag1^{-/-} mice comparing activity of anti-EGFR antibodies against established A431 tumors. Tumor volume is plotted against day after tumor cell injection. Antibodies were dosed 5 mg/kg every 10 d starting on day 10 (indicated by the arrows). $n = 9$ mice/group. *, $P = 0.005$ at 35 d.

Several studies have demonstrated that antibodies to epidermal growth factor receptor (EGFR) are internalized. Moreover, nonlinear dose-dependent clearance has been observed in monkeys and humans, leading to the hypothesis that receptor-dependent internalization makes a major contribution to clearance of anti-EGFR antibodies^{11,12}. The M428L/N434S Xtend variant was constructed in a humanized version (huC225) of the anti-EGFR antibody cetuximab (C225)¹³ (Erbix), which is approved for the treatment of colorectal and head and neck cancers. We refer to this pharmacokinetically enhanced anti-EGFR antibody as Xtend-EGFR. The improvement in affinity for human FcRn resembled that observed for anti-VEGF; binding to human EGFR antigen was unperturbed, and both cetuximab and humanized cetuximab cross-react with cynomolgus EGFR¹⁴ (data not shown). The 7.5 mg/kg dose chosen for this study is in a range where the dose-clearance relationship is nonlinear¹⁴. In our hands cetuximab had a half-life of 1.5 d (Supplementary Table 2), similar to previously published data at the same dose (2.7–3.1 d)¹⁴. Consistent with the bevacizumab results, the Xtend variant anti-EGFR increased half-life to 4.7 d, reflecting a 3.1-fold improvement (Fig. 1b and Supplementary Table 2). We have thus demonstrated pharmacokinetic improvements conferred by Fc engineering of an internalizing antibody, even when it is dosed within the nonlinear clearance regime.

We performed pharmacokinetic experiments in C57BL/6J (B6)-background mice that are homozygous for a knockout allele of murine FcRn and heterozygous for a human FcRn transgene (mFcRn^{-/-},

hFcRn⁺)¹⁵, referred to here as hFcRn mice. A description of these experiments is provided in the **Supplementary Methods**. Serum concentration data for native IgG1 and Xtend anti-VEGF antibodies showed a dramatic enhancement in half-life for the variant relative to native IgG1 (Fig. 2a), improving half-life fourfold from ~3–12 d (Supplementary Table 2). In the anti-EGFR context, the Xtend variant improved half-life to 13.9 d relative to 2.9 d for cetuximab, resulting in an enhancement of about fivefold (Fig. 2b and Supplementary Table 2). The IgG1 version of huC225 also had a relatively short half-life of 2 d (data not shown). We observed a general correlation between antibody half-life and FcRn affinity at pH 6.0 across two anti-VEGF studies and one anti-EGFR hFcRn pharmacokinetic study. The pharmacokinetic results for individual variants and native IgG1 were consistent and reproducible between the three studies (Supplementary Fig. 2b–c and Supplementary Table 2).

To test whether the slower clearance of our pharmacokinetic-engineered antibodies results in improved exposure-related pharmacology, we developed an hFcRn transgenic, Rag1^{-/-} immunodeficient mouse strain (Supplementary Methods and Supplementary Fig. 3). For VEGF, SKOV-3 tumors were established to 25–60 mm³ and then treated with either vehicle or 5 mg/kg native IgG1 or Xtend variant bevacizumab every 10 d. This dosing schedule approximated the half-life of the Xtend variant, but was three to four half-lives longer than the half-life of the native IgG1 version (Supplementary Table 2). A statistically greater level of tumor reduction ($P = 0.028$ at study termination) was observed for the Xtend variant relative to the native IgG1 version (Fig. 2c). A similar study in hFcRn/Rag1^{-/-} mice comparing Xtend-EGFR to a native IgG1 version showed similar improvements in tumor reduction ($P = 0.005$) against established A431 epidermoid carcinoma tumors (Fig. 2d). Consistent with the pharmacokinetic results in hFcRn mice (Fig. 2a–b), the variants reduced clearance in the hFcRn/Rag1^{-/-} mice (Supplementary Fig. 3a–b), demonstrating an inverse correlation between tumor volume and serum concentration of antibody at study termination. These results indicate that the slower clearance of the variant antibodies leads to higher drug exposure and consequently superior tumor-suppressing pharmacology. Additional studies comparing various dosing intervals of the Xtend variants and parent antibodies will be necessary to precisely define dosing regimens for optimal clinical benefit. However, the results described here firmly establish a positive correlation between pharmacokinetic enhancement and *in vivo* efficacy.

Despite the reasonably long half-lives of monoclonal antibodies, market pressures for higher patient convenience and compliance continue to drive antibody drug programs toward less frequent dosing schedules. Yet, because of the potential loss in efficacy when the dosing frequency is not justified by the pharmacokinetics of the drug, the critical issue of whether slower antibody clearance through Fc engineering leads to superior exposure-dependent efficacy has remained unresolved. Our results indicate that, for at least some therapies, efficacy can be preserved with extended dosing intervals enabled by pharmacokinetic engineering. This work thus paves the way for a new generation of antibody therapies and biologically superior versions of approved antibody drugs that deliver finer control over dosing while providing greater convenience to patients.

Note: Supplementary information is available on the Nature Biotechnology website.

ACKNOWLEDGMENTS

We thank The Jackson Laboratory IAX West and SNBL USA for carrying out pharmacokinetic experiments, B. Dahiya for helpful discussions, and A. Eivazi, D.-H.T. Nguyen, H. Herman, J.M. Jacinto and U.S. Muchhal for technical contributions.

AUTHOR CONTRIBUTIONS

J.Z., A.K.C., H.M.H., G.A.L., D.C.R. and J.R.D. designed the research, J.Z., A.K.C., H.M.H., S.K., I.W.L.L. and T.J.S. carried out experiments, and J.Z., G.A.L. and J.R.D. wrote the manuscript.

COMPETING INTERESTS STATEMENT

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturebiotechnology/>.

Published online at <http://www.nature.com/naturebiotechnology/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

1. Roopenian, D.C. & Akilesh, S. *Nat. Rev. Immunol.* **7**, 715–725 (2007).
2. Presta, L.G.. *Curr. Opin. Immunol.* **20**, 460–470 (2008).
3. Datta-Mannan, A., Witcher, D.R., Tang, Y., Watkins, J. & Wroblewski, V.J. *J. Biol. Chem.* **282**, 1709–1717 (2007).
4. Gurbaxani, B., Dela Cruz, L.L., Chintalacharuvu, K. & Morrison, S.L. *Mol. Immunol.* **43**, 1462–1473 (2006).
5. Dall'Acqua, W.F., Kiener, P.A. & Wu, H.. *J. Biol. Chem.* **281**, 23514–23524 (2006).
6. Hinton, P.R. *et al. J. Biol. Chem.* **279**, 6213–6216 (2004).
7. Hinton, P.R. *et al. J. Immunol.* **176**, 346–356 (2006).
8. Yeung, Y.A. *et al. J. Immunol.* **182**, 7663–7671 (2009).
9. Presta, L.G. *et al. Cancer Res.* **57**, 4593–4599 (1997).
10. Lin, Y.S. *et al. J. Pharmacol. Exp. Ther.* **288**, 371–378 (1999).
11. Fan, Z., Lu, Y., Wu, X. & Mendelsohn, J. *J. Biol. Chem.* **269**, 27595–27602 (1994).
12. Lammerts van Bueren, J.J. *et al. Cancer Res.* **66**, 7630–7638 (2006).
13. Naramura, M., Gillies, S.D., Mendelsohn, J., Reisfeld, R.A. & Mueller, B.M. *Cancer Immunol. Immunother.* **37**, 343–349 (1993).
14. Imclone Systems, Inc Biologic License Application 125084, Erbitux (Cetuximab) (US Food and Drug Administration, Feb. 12, 2004). (http://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125084_ERBITUX_PHARMR_P2.PDF).
15. Petkova, S.B. *et al. Int. Immunol.* **18**, 1759–1769 (2006).